Randomized, Double-blind, Placebo-controlled Phase III Study to Assess the Efficacy and Safety of Abatacept in Patients With Primary Sjogren's Syndrome
Phase of Trial: Phase III
Latest Information Update: 08 Jan 2016
At a glance
- Drugs Abatacept (Primary)
- Indications Sjogren's syndrome
- Focus Therapeutic Use
- Acronyms ASAPIII
- 10 Jun 2017 Biomarkers information updated
- 21 Aug 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
- 10 Jun 2014 Planned End Date changed from 1 Jun 2017 to 1 Jul 2018 as reported by ClinicalTrials.gov record.